The biotechnology sector continues to witness significant investments in innovative therapeutic solutions, with Helex emerging as a promising player in the gene therapy space. The Hyderabad based startup has successfully closed a $3.5 million seed funding round, marking a critical milestone in its mission to develop curative treatments for autosomal dominant polycystic kidney disease.
Strategic Investment for Unmet Medical Needs
Pi Ventures spearheaded the funding round, joined by notable investors including Bluehill.VC and the US based venture capital firm SOSV. This latest capital infusion elevates Helex’s cumulative funding beyond the $6 million threshold, providing essential resources to advance its lead therapeutic candidate through preclinical development stages.
The focus on ADPKD addresses a substantial gap in medical treatment options. This progressive genetic condition impacts approximately 12 million patients globally, with India accounting for nearly five percent of chronic kidney disease cases attributed to this disorder. Currently, affected individuals primarily rely on symptom management rather than disease modifying interventions, highlighting the urgent need for innovative therapeutic approaches.
Pioneering Technology Platform
Helex distinguishes itself through its sophisticated integration of multiple cutting edge technologies. The company has developed a proprietary lipid nanoparticle delivery system capable of transporting genetic payloads directly to kidney cells with precision. This platform operates in conjunction with artificial intelligence powered drug design tools that leverage deep learning algorithms, genomics data, and high throughput sequencing information to optimize therapeutic candidates.
The startup’s flagship program aims to deliver a transformative single dose treatment that could halt or significantly decelerate disease progression. This non viral gene editing approach represents a departure from traditional therapeutic modalities and holds potential for broader applications across various kidney related disorders.
Foundation and Future Trajectory
Established in 2021 by co-founders Poulami Chaudhuri, Anirudh Nishtala, and Rohini Kalvakuntla, Helex benefited from its incubation at ASPIRE-BioNEST at the University of Hyderabad. The founding team’s vision centers on making advanced genomic medicine accessible and economically viable for patients worldwide.
As Helex advances toward clinical trials, the company exemplifies India’s growing capabilities in developing sophisticated biopharmaceutical solutions. The successful funding round positions the startup to potentially reshape treatment paradigms for millions of patients currently facing limited therapeutic options for genetic kidney diseases.
Also Read: Fireside Ventures Backs Oroos Confectionery with INR 20 Crore Capital Infusion
